To determine the roles of these HDACs in pancreatic cancer cell growth and survival, we used three different HDACIs, MGCD0103 (Mocetinostat, a class I-selective HDACI) [29], MC1568 (a class IIa-selective HDACI) [30]–[32], and Tubastatin A (a novel HDAC6-specific inhibitor) [33]. This evidence concerns the gene HDAC6 and pancreatic neoplasm.